Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Market Cap	27.07B
Revenue (ttm)	1.80B
Net Income (ttm)	-222.18M
Shares Out	n/a
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	467
Average Volume	658
Open	267.65
Previous Close	274.14
Day's Range	266.00 - 272.60
52-Week Range	143.66 - 272.60
Beta	n/a
RSI	57.43
Earnings Date	May 1, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HD2

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD